Litva - litovčina - SMCA (Valstybinė vaistų kontrolės tarnyba)

n.v. organon - rokuronio bromidas - injekcinis ar infuzinis tirpalas - 10 mg/ml - rocuronium bromide

Litva - litovčina - SMCA (Valstybinė vaistų kontrolės tarnyba)

kela n.v. (belgija) - geriamieji milteliai - 1 g miltelių yra: oksitetraciklino (hidrochlorido) - 800,0 mg. - kiaulėms, veršeliams, paukščiams, sergantiems infekcinėmis ligomis, kurių sukėlėjai jautrūs oksitetraciklinui, gydyti.

Litva - litovčina - SMCA (Valstybinė vaistų kontrolės tarnyba)

bela-pharm gmbh & co. kg (vokietija) - injekcinis tirpalas - 1 ml yra: linkomicino hidrochlorido monohidrato - 56,7 mg, spektinomicino sulfato tetrahidrato - 151,2 mg. - galvijams (veršeliams), kiaulėms, šunims ir katėms, sergantiems infekcinėmis ligomis, kurių sukėlėjai jautrūs linkomicinui ir spektinomicinui, gydyti.

Litva - litovčina - SMCA (Valstybinė vaistų kontrolės tarnyba)

b.braun melsungen ag - natrio chloridas/kalio chloridas/magnio chloridas heksahidratas/kalcio chloridas dihidratas/natrio acetatas trihidratas/l-obuolių rūgštis - infuzinis tirpalas - 6,8 g/0,3 g/0,2 g/0,37 g/3,27 g/0,67 g/1000 ml - electrolytes

Litva - litovčina - SMCA (Valstybinė vaistų kontrolės tarnyba)

pharmaswiss Česká republika s.r.o. - finasteridas - plėvele dengtos tabletės - 5 mg - finasteride

Európska únia - litovčina - EMA (European Medicines Agency)

novartis europharm limited - erenumab - migrenos sutrikimai - analgetikai - aimovig skiriama profilaktika migrena, suaugusiems žmonėms, kurie turi ne mažiau kaip 4 migrena dienų per mėnesį, kai pradėti gydymą su aimovig.

Európska únia - litovčina - EMA (European Medicines Agency)

stada arzneimittel ag - bevacizumabas - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antinavikiniai vaistai - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. daugiau informacijos apie žmogaus epidermio augimo faktoriaus receptorių 2 (her2) būklę rasite 5 skyriuje. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. daugiau informacijos apie her2 statusą rasite 5 skyriuje. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Litva - litovčina - SMCA (Valstybinė vaistų kontrolės tarnyba)

chanelle pharmaceuticals manufacturing ltd. (airija) - injekcinis tirpalas - 1 ml tirpalo yra: veikliosios (-iųjų) medžiagos (-ų): ivermektino 10 mg; klorsulono 100 mg. - jaučiams ir pieniniams galvijams (ne laktacijos metu), užsikrėtusiems skrandžio, žarnyno, plaučių, akių nematodais, odos parazitais, sergantiems fasciolioze, gydyti ir profilaktiškai.